AFP
REGN icon

Ausdal Financial Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Ausdal Financial Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Sell
561
-90
-14% -$68.9K 0.02% 638
2025
Q4 		$502K Buy
+651
New +$442K 0.02% 554

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ausdal Financial Partners's REGN Position: Q1 2026 in Review

Ausdal Financial Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q1 2026, selling an estimated $68.9K and leaving 561 shares worth $434K. The position accounts for 0.02% of the portfolio, ranked #638.

Ausdal Financial Partners first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $502K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ausdal Financial Partners held 561 shares of Regeneron Pharmaceuticals worth $434K as of Q1 2026.
  • Ausdal Financial Partners sold 90 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $68.9K.
  • Regeneron Pharmaceuticals made up 0.02% of Ausdal Financial Partners's portfolio in Q1 2026, its #638 holding.
  • Ausdal Financial Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Ausdal Financial Partners's Regeneron Pharmaceuticals position peaked at $502K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.